Baycol product liability litigation
Executive Summary
Bayer has received 5,700 lawsuits related to the Baycol withdrawal, "almost entirely" from the U.S., Chairman Werner Wenning says during Nov. 12 analysts meeting. "Many of the recently-filed complaints are simply copied from other complaints; for example, a single firm has filed 2,500 virtually identical complaints." Further, "where we have been able to evaluate preliminary facts obtained from plaintiffs through discovery, we have found that the majority of plaintiffs are not claiming that they were hospitalized or developed rhabdomyolysis - the side-effect that led to the withdrawal of Baycol." Bayer has settled 190 cases; more than 150 of the suits filed are class actions. Baycol (cerivastatin) was withdrawn in August 2001 (1"The Pink Sheet" Aug. 13, 2001, p. 4)...
You may also be interested in...
Baycol Withdrawal Gives Boost To Pravachol; Will Crestor NDA Be Affected?
Bristol-Myers Squibb's Pravachol is gaining share in the retail market in the early days following the withdrawal of Bayer's Baycol, prescription tracking data from ArcLight indicate.
Despite 'Remarkable' ROI On Women’s Health Investments, Money Still Lacking
Recent US government initiatives and growing investor interest are important for developing female-specific therapeutics, but funding is not yet where it should be.
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues in an interview with Scrip.